Subcellular distribution of p210BCR-ABL in CML cell lines and primary CD34+ CML cells

Leukemia

Volumn 22, Issue 3, 2008, Pages 559-571

  Patel, H ^a   Marley, S B ^a   Greener, L ^a   Gordon, M Y ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CT10 REGULATOR LIKE PROTEIN; IMATINIB; MONOCLONAL ANTIBODY; PROTEIN P120; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CELL MATURATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; COMPLEX FORMATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT;

EID: 40749161512     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405057     Document Type: Article

References (49)

1. Nowell P, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497-1501.
2. Konopka JB, Witte ON. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 1985; 5: 3116-3123.
3. Pendergast AM, Ouilliam LA, Cripe LD, Bassing CH, Dai Z, Der CJ et al BCR-ABI induced oncogenesis is mediated by direct interaction with the SH2 domain of GRB-2 adaptor protein. Cell 1993; 75: 175-185.
4. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994; 269: 22925-22928.
5. BCR-ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 1995; 270: 29145-29150.
6. Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E et al The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 1996; 12: 839-846.
7. Pelicci G, Lanfrancone L, Salcini AE, Romano A, Mele S, Borrello MG et al. Constitutive phosphorylation of SHC proteins in human tumors. Oncogene 1995; 11: 899.
8. Skourides PA, Perera SA, Ren R. Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins. Oncogene 1999; 18: 1165-1176.
9. Marley SB, Gordon MY. Chronic myeloid leukaemia: Stem cell derived but progenitor cell driven. Clin Sci (London) 2005; 109: 13-25.
10. Maxwell SA, Kurzrock R, Parsons SJ, Talpaz M, Gallick GE, Kloetzer WS et al. Analysis of P21Obcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res 1987; 47: 1731-1739.
11. Guo J, Wang J, Arlinghaus R. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Research 1991; 51: 3048-3051.
12. Patel H, Marley SB, Gordon MY. Detection in primary chronic myeloid leukaernia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2. Genes Chromosomes Cancer 2006; 45: 1121-1129.
13. ten Hoeve J, Morris C, Heisterkamp N, Groffen J. Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene 1993; 8: 2469-2474.
14. de Jong R, Haataja L, voncken JW, Heisterkamp N, Groffen J. Tyrosine phosphorylation of murine CRKL. Oncogene 1995; 11: 1469-1474.
15. Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW. identification of Crkl as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myellogenous leukemia cells blood 1994; 84: 2912-2918.
16. ten Hoeve J, Kaartinen V, Fioretos T, Haataja L. Cellular inter-action of CRKL, an SH2-SH3 adaptor protein. Cancer Res 1994; 54: 2563-2567.
17. ten Bosch GJA, Kessler JH, Blom J, Joostan AM, Gambacorti-Passerini C, Melief CJM et al. BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of Crkl phosphorylation. Br J Haematol 1998; 103: 1109-1115.
18. + leukemia. Blood 1994; 84: 1731-1736.
19. White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005; 106: 2520-2526.
20. Hamilton A, Elrick L, Myssina S, Copland M, Jorgensen H, Melo JV et al. BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry. Leukemia 2006; 20: 1035-1039.
21. Phee H, Rodgers. W, Coggeshall KM. Visualization of negative signaling in B cells by quantitative confocal microscopy. Mol Cell Biol 2001; 21: 8615-8625.
22. Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 1993; 92: 1925-1939.
23. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2007; 7: 228-234.
24. Melo J. Inviting leukemic cells to waltz with the devil. Nat Med 2001; 7: 156-157.
25. Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with ImageJ. Biophotonics Int 2004; 11: 36-42.
26. Manders EEM, Verbeek FJ, Aten JA. Measurement of co-localization of objects in dual-colour confocal images. J Microsc 1993; 169: 375-382.
27. Gomperts BD, Kramer IM, Tatham PER. Signal Transduction, Origins and Personalities. Signal Transduction. Academic Press: London, UK, 2002, pp 1-14.
28. Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phȩnotype. Blood 1996; 88: 2375-2384.
29. de Lemos JAR, de Oliveria CM, Scerni ACC, Bentes AQ, Beltrao AC, Bentes IRG et al. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. Genet Mol Res 2005; 4: 803-811.
30. Perego RA, Costantini M, Cornacchini G, Garganini L, Biachi C, Pungolino E et al. Possible influences of B2A2 and B3A3 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer 2000; 63: 1395-1401.
31. Mills KI, Benn P, Birnie GD. Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood 1991; 75: 1155-1161.
32. Guinn BA, Evely RS, Walsh V, Gikes AF, Burnett AK, Mills KI. An in vivo and in vitro comparison of the effects of b2a2 and b3a2 p210BCR-ABL splice variants on murine 32D cells. Leuk Lymphoma 2000; 37: 393-404.
33. Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) target an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532-4539.
34. Deng LW, Chiu I, Strominger JL. MLL 5 protein forms intracellular foci, and overexpression inhibits cell cycle progression. Proc Natl Acad Soc 2004; 101: 757-762.
35. Chen J, Yu WM, Daino H, Broxmeyer HE, Druker BJ, Qu CK. SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood 2007; 109: 778-785.
36. Heaney C, Kolibaba K, Bhat A, Oda T, Ohno S, Fanning S et al. Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation. Blood 1997; 89: 297-306.
37. de Jong R, ten Hoeve J, Heisterkamp N, Groffen J. Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site. Oncogene 1997; 14: 507-513.
38. Senechal K, Heaney C, Druker B, Sawyers C. Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells. Mol Cell Biol 1998; 18: 5082-5090.
39. Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H et al Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene 2002; 21: 1423-1433.
40. Bhat A, Kolibaba K, Oda T, Ohno-Jones S, Heaney C, Druker BJ. Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells. J Biol Chem 1997; 272: 16170-16175.
41. Puil L, Lui J, Gish G, Mbamalu G, Bowtell D, Pelicci PG et al. Bcr-Abl oncoproteins bind directly to activators of the RAS signalling pathway. EMBO J 1994; 13: 764-773.
42. Tauchi T, Boswell SH, Leibowitz D, Broxmeyer HE. Coupling between p210bcr-abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to RAS activation pathway. J Exp Med 1994; 179: 167-175.
43. Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K et al Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002; 1: 479-492.
44. Gaston I, Johnson KJ, Oda T, Bhat A, Reis M, Langdon W et al. Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl. Exp Hematol 2004; 32: 113-121.
45. Ren R, Ye Z, Baltimore D. Abl protein-tryrosine kinase selects the Crk adaptor as a substrate using SH3-binding sites. Genes Dev 1994; 8: 783-795.
46. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-567.
47. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691-3698.
48. Marley SB, Deininger MW, Davidson RJ, Goldman JM, Gordon MY. The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia. Exp Hematol 2000; 28: 551-557.
49. Nishihara T, Miura Y, Tohyama Y, Mizutani C, Hishita T, Ichiyama S et al. Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: Suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes. Int J Hematol 2003; 78: 233-240.